While at Brunswick, she has worked on Bayer’s $66 billion acquisition of Monsanto, on behalf of Marriott in its contentious $13 billion acquisition of Starwood, for Freeport-McMoRan in defense against Carl Icahn, and on behalf of Arconic against Elliott Management.
Prior to joining Brunswick, Rebecca was a proxy solicitor at D.F. King focusing on contested shareholder meetings. She has extensive experience defending public companies from board takeovers and hostile tender offers, and counseling activist investors launching proxy fights for majority and minority board representation. During her role at D.F. King she worked on behalf of activists during the Canadian Pacific, CSX, Biogen Idec, Forest Laboratories and Target proxy fights, among others. She also has deep expertise advising on compensation and corporate governance matters at annual/special shareholder meetings as well as shareholder votes around contentious M&A proposals.
Rebecca has a B.A. in economics and psychology from Bucknell University and an M.B.A. from New York University, Stern School of Business.
In today’s era of increased corporate engagement, stakeholders of all kinds are voicing opinions on how a company and its management should deliver value. As the number of activist investor campaigns continue to increase around the world, some recent developments as the activism landscape matures:
By Amelia Pan
27 February 2019